Hudock Capital Group LLC raised its position in Teva Pharmaceutical Industries Limited by 37.6% in the second quarter. Hudock Capital Group LLC now owns 2,064 shares of the company's stock worth $103,000 after buying an additional 564 shares during the period. The average analysts gave this company a mean recommendation of 2.10. Bank of New York Mellon Corp now owns 14,868,642 shares of the company's stock worth $746,852,000 after buying an additional 1,972,944 shares in the last quarter. Finally, JFS Wealth Advisors LLC increased its position in Teva Pharmaceutical Industries Limited by 139.0% in the third quarter. Non-GAAP earnings per share was $1.38, up from $1.28 in the corresponding quarter of 2015 and higher than the analysts' estimate of $1.36. The stock had a trading volume of 7,340,881 shares. Teva hit a record high of $72.31/share in 2015 and is now trading near $32/share. The firm has a market cap of $32.67 billion, a P/E ratio of 18.73 and a beta of 0.58.
The stock's price switched up 1.39% 20-Days Simple Moving Average, dropped -3.41% from 50-Days Simple Moving Average and fell -24.95% from 200 Days Simple Moving Average. On average, analysts anticipate that Teva Pharmaceutical Industries Limited will post $5.11 EPS for the current fiscal year. The company earned $6.25 billion during the quarter, compared to analysts' expectations of $6.26 billion.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) is now showing its ROA (Return on Assets) of 2.4%.
Teva Pharmaceutical Industries Limited (NYSE:TEVA) last issued its quarterly earnings results on Monday, February 13th. During the same quarter in the previous year, the company posted $1.35 EPS.
It will pay a quarterly dividend of 34 cents per ordinary share and $17.50 per mandatory convertible preferred share. Investors of record on Thursday, March 2nd will be issued a $0.34 dividend. This represents a $1.36 annualized dividend and a yield of 4.00%. Teva Pharmaceutical Industries Limited's payout ratio is 67.44%.
According to FactSet data, TEVA stock has received different ratings from Financial Analysts. If you are accessing this news story on another site, it was copied illegally and reposted in violation of US and global copyright legislation.
"Teva Pharmaceutical Industries Limited (TEVA) Issues FY17 Earnings Guidance" was reported by Chaffey Breeze and is the property of of Chaffey Breeze.
Investors say Teva, which faces pricing pressure in its core generics business and recently lost patent protection on its key branded drug Copaxone for multiple sclerosis, must choose a new CEO with extensive pharmaceutical experience.
A number of analysts have recently issued reports on TEVA shares. RBC Capital Markets reaffirmed an "outperform" rating and set a $42.00 target price on shares of Teva Pharmaceutical Industries Limited in a report on Tuesday.
Price Target is basically a projection of future price of a company's stock by the expert analysis of investment analysts or investment firms.
Deutsche Bank has a Buy rating and cut its price target to $45 from $48.
Teva may also opt to sell other non-core assets, such as its active pharmaceutical ingredients business, the people said.
Research-and-development costs jumped 53% to $684 million, with expenses rising for both generics and specialty as well as from an upfront payment of $160 million to Celltrion to commercialize two biosimilar drugs.
Among analysts and investors, a widespread belief is that Teva could split in two-one side, the company's generics business, the other, its branded drug company.
Global sales of Copaxone rose 6 percent in the quarter to $1.0 billion.